"Making money" is the password to Revolution's mythical 100 billion achievement.
In 2026, Revolution is undoubtedly the most popular Biotech company globally. The company has achieved a breakthrough in the field of undruggable targets, bringing a new treatment plan for pancreatic cancer, known as the "king of cancers." This has not only attracted high - level attention from the industry but also become a core target pursued by capital.
Why can Revolution stand out? There are many answers. Today, let's not talk about pipelines and R & D. Instead, let's discuss the core ability beyond R & D: financing ability. For innovative drug companies, time is the most expensive asset, and capital is the core fuel for R & D advancement.
Revolution's strong financing ability has contributed significantly to its current industry status. Since its IPO, its cumulative financing scale has been nearly $7.6 billion.
It's no exaggeration to say that Revolution is one of the most proficient companies in "raising money" among global Biotech companies at present. Its financing strategy and capital operation logic are highly instructive and essentially answer a question:
Financing, large - scale financing, is not just about self - praise. It also relies on technology and art.
/ 01 / Money - burning black hole & money - raising expert
Innovative drug R & D is an industry with high investment and long - cycle, and Revolution is no exception.
Since its establishment, the company has been in a state of continuous loss, earning the title of a money - burning black hole. From its listing in 2020 to the end of 2025, in just five years, the total net loss reached $2.2 billion.
In 2026, the intensity of money - burning is still increasing. In the first quarter, the net loss reached $453.8 million, a year - on - year increase of 112.6%.
The huge loss mainly comes from high - intensity R & D. As of now, Revolution has spent more than $3 billion on R & D expenses alone, and the record is constantly being refreshed. In the first quarter of 2026, R & D expenses reached a new high, with a year - on - year increase of 67.2% to $344 million.
This money - burning speed is not unexpected. After all, Revolution is very aggressive in both pipeline layout and clinical development.
Currently, the company already has 4 RAS(ON) inhibitors in the clinical stage, covering multiple directions such as pan - RAS, KRAS G12D, and KRAS G12C. It is also laying out next - generation drug - resistance pipelines.
More importantly, the company is simultaneously promoting research on first - line, second - line, adjuvant therapy, and combination therapy for multiple cancers such as pancreatic cancer and lung cancer, and has completed the enrollment of more than 2,500 patients. Among them, there are more than 10 ongoing clinical studies on two drugs, RMC - 6236 and RMC - 9805.
On this basis, the company still stated in its first - quarter financial report in 2026 that it will continue to increase the expected R & D investment to support the rapid progress of the pipeline.
Obviously, Revolution is not worried about capital issues. Because compared with its money - burning speed, its "money - attracting ability" is stronger. Since its listing, the company has completed nearly 10 equity financings, with a total financing of $7.55 billion (including expected debt financing).
As of the first quarter, Revolution has a cash reserve of $4 billion, which is sufficient to support multiple Phase III clinical trials, commercialization preparations, and next - generation pipeline R & D for 4 RAS inhibitors.
/ 02 / "Rhythm master"
Looking back at Revolution's financing history, it is most appropriate to describe it as a "rhythm master." It doesn't just simply have financing ability. Instead, it deeply understands the laws of the capital market and has formed a clear capital strategy: Almost every time after the disclosure of key data from core clinical trials, it will quickly initiate a share issuance. Taking advantage of the upward window of valuation catalyzed by good news, it can obtain capital with the lowest equity dilution cost to reserve ammunition for subsequent R & D.
On February 27, 2023, the company's financial report first announced the early positive data of RMC - 6236 in the treatment of NSCLC and PDAC. The market began to truly realize the potential of pan - RAS. This also promoted the rise of the secondary - market stock price, with a 9.81% increase on the day of the financial report release.
This was not easy for Revolution, whose stock price was sluggish at that time. The company seized the opportunity and completed a share issuance for financing on March 2, ultimately obtaining a profit of $345 million. Subsequently, the company significantly accelerated the progress of dose exploration, expansion cohorts, and combination therapy research for drugs such as RMC - 6236.
This kind of scenario occurred many times later.
At the end of 2024, as RMC - 6236 and RMC - 9805 successively disclosed positive data in the treatment of PDAC, Revolution's stock price also had a new round of increase, reaching $50 per share.
Similarly, after the stock price increase, the company quickly completed another share issuance. On December 5, 2024, three days after the release of the latest data, the company announced that it had raised $862.5 million through a share issuance, which accelerated the progress of the global multi - center Phase III clinical trial of RMC - 6236.
The most recent share issuance occurred on April 13, 2026, and the announcement of the share issuance was on the same day as the data disclosure.
Before this, several merger rumors had pushed the company's stock price up continuously, from $70 at the end of 2025 to $90 per share. After the release of the results of the key Phase III RASolute 302 clinical trial of RMC - 6236, the company's stock price rose again, breaking through to $150.
At this time, the company announced a $2 - billion share issuance at $142 per share. After the share issuance was completed, Revolution's cash reserve reached $4 billion, which is sufficient to support the company's R & D and commercialization in the next few years.
Looking back in hindsight, Revolution's decision to raise funds during the favorable window each time may not be an inevitable choice after precise prediction, but it is undoubtedly the wisest decision at that time - after all, no one can accurately predict the subsequent stock price and market conditions.
Under this logic, seizing the most certain clinical good news "right now" and directly converting market sentiment into R & D capital and pipeline progress speed is obviously the best choice. And Revolution is willing to pay for this definite R & D acceleration.
/ 03 / "Don't wait until it's absolutely necessary to raise funds"
In addition to its precise financing rhythm, Revolution's capital operation is also extremely flexible: it raises funds resolutely when the market sentiment is high, and makes good use of external leverage to continuously inject capital into R & D when the industry is in a downturn.
The largest cash flow in the company's history came from a reverse merger with EQRx at the end of 2023.
At that time, Revolution's own market value was only about $3 billion, but it still chose to complete the acquisition through an all - stock transaction. According to the transaction terms, EQRx would receive $200 million worth of shares at $26 per share, and the remaining $870 million worth of shares would be priced at a 6% discount based on the 5 - day average price.
This operation was a stroke of genius. In 2023, the US Biotech sector was in a slump. Directly issuing new shares would easily lead to valuation suppression, soaring financing costs, and even fundraising failure; By acquiring the listed shell company EQRx, the company cleverly bypassed the emotional constraints of direct financing in the secondary market, and the overall discount rate was extremely low. It completed a large - scale cash injection in a bear - market environment. Subsequently, it was proven that this capital became an important foundation for the key registration - based clinical research of the core pipeline RMC - 6236.
Another textbook - level capital operation was a major cooperation with Royalty Pharma. On June 24, 2025, the two parties reached a $2 - billion flexible financing agreement, including a $1.25 - billion royalty advance payment and a $750 - million credit line. Royalty Pharma will obtain a share of the future sales of RMC - 6236 after its listing. It is worth noting that before the transaction was finalized, Revolution already had a $2 - billion cash reserve on its books; and RMC - 6236 had obtained the FDA's breakthrough therapy designation, leading the commercialization progress among similar competitors. The company was fully capable of independently bearing the subsequent clinical and early - stage commercialization investment.
But as CEO Mark Goldsmith said, "We need as much capital as possible." The value of this financing not only lies in accelerating clinical progress but also gives the company the confidence to carry out independent commercialization. The company clearly stated in the announcement that this capital will support the implementation of its global independent development and commercialization strategy.
The sufficient cash reserve also gives Revolution the confidence to reject acquisitions by giants. At the beginning of this year, there were continuous market rumors that multinational pharmaceutical companies such as AbbVie and AstraZeneca were interested in acquiring the company, but the transaction did not materialize in the end. However, the market did not question its independent operation ability. Instead, it continuously raised the valuation, and the company's current market value has exceeded $30 billion.
/ 04 / Summary
From a continuously money - burning Biotech startup to an industry upstart with a market value exceeding $30 billion, Revolution's rise is never the result of a single factor. It is the perfect synergy of R & D strength, clinical rhythm, and capital wisdom.
Its rise not only proves to the market that in - depth exploration of differentiated tracks and tackling the field of undruggable targets can lead to a way out of the predicament; it also deeply reveals a core truth - for innovative drug companies, "being good at raising money" is as important as "being good at R & D."
Without such strong financing ability and forward - looking capital layout, Revolution might have been forced to sell itself to a giant in the money - burning war, and the market - value myth would never have been possible.
This article is from the WeChat official account "Amino Observation" (ID: anjiguancha). Author: Amino Jun. It is published by 36Kr with authorization.